Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Intensity Therapeutics, Inc. ( (INTS) ) is now available.
On September 10, 2025, Intensity Therapeutics, Inc. provided an update on its INVINCIBLE-4 study, revealing a pathological complete response in the first evaluated patient of Cohort A. Despite a favorable safety profile, localized skin irritation led to a pause in new patient enrollment to assess data and make necessary adjustments.
The most recent analyst rating on (INTS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of cancer immunotherapy treatments.
Average Trading Volume: 4,432,898
Technical Sentiment Signal: Sell
Learn more about INTS stock on TipRanks’ Stock Analysis page.